Brief: Seelos Therapeutics Announces Completion Of Enrollment Of Its Phase II/III Trial Of SLS-005
13/02/2023 13:30
Feb 13 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT OF
ITS
PHASE II/III TRIAL OF SLS-005 IN AMYOTROPHIC LATERAL SCLEROSIS
ON THE HEALEY ALS PLATFORM
* SEELOS THERAPEUTICS INC - RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED STUDY IS EVALUATING SLS-005 IN 160 PATIENTS
OVER 24 WEEKS
* SEELOS THERAPEUTICS INC - SEELOS ANTICIPATES DELIVERING
TOPLINE
DATA IN SECOND HALF OF 2023
Source text for Eikon: ID:nPn2CycHBa
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio